House bill would negate Amgen provision in "fiscal cliff" deal

01/24/2013 | Hill, The

Rep. Peter Welch, D-Vt., introduced a bill that would subject a class of kidney drugs including Amgen's Sensipar to Medicare price controls. The deal approved to avert the "fiscal cliff" included language delaying price controls by two years, which critics say would cost Medicare close to $500 million.

View Full Article in:

Hill, The